Researchers engineered functionally enhanced proximal tubules from induced pluripotent stem cell organoids, reporting improved drug transport performance and disease modeling fidelity for preclinical screening. The work describes proximal-tubule maturation and functional readouts aimed at capturing more clinically relevant transport biology than many earlier organoid formats. The authors also positioned the platform as regenerative, supporting both toxicity and efficacy screening where renal handling of compounds is a major determinant. For pharma and CROs developing renally cleared therapies, the study offers a step toward better in vitro renal pharmacology—potentially reducing late-stage failures driven by transport or transporter-dependent metabolism differences.
Get the Daily Brief